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A hydrogel was developed from 70 kDa dextran (DEX-70) and praziquantel (PZQ) incorporated as a 
model drug. Biopharmaceutical properties, such as solubility and dissolution rate, were analysed in the 
design of the hydrogel. Furthermore, the hydrogel was also characterized by IR spectroscopy and DSC. 
Tests of the swelling rate showed that the hydrogel swelled slowly, albeit faster than the rate for the 
free polymer. In dissolution tests, the hydrogel released the drug slowly and continuously. This slow 
release was similar to that observed in the swelling tests and resulted in controlled release of the drug. 
Thus, this dextran is a suitable polymer for the development of hydrogels as vehicles for the controlled 
release of drugs.
Uniterms: Hydrogel/development. Hydrogel/biopharmaceutical properties. Dextran/hydrogel 
development. Praziquantel/controlled release. Hydrogel/swelling test.
Um hidrogel foi desenvolvido a partir de dextrano 70 kDa (DEX-70) e praziquantel incorporado (PZQ) 
como fármaco modelo. Propriedades biofarmacêuticas, como solubilidade e velocidade de dissolução, 
foram analisadas no desenvolvimento do hidrogel. Além disso, o hidrogel também foi caracterizado 
por espectroscopia na região do infravermelho e calorimetria diferencial exploratória (DSC). Testes 
da taxa de intumescimento mostraram que o hidrogel intumesce lentamente, embora tenha sido mais 
rápido do que a taxa do polímero livre. Nos testes de dissolução, o hidrogel liberou o fármaco lenta e 
continuamente. Esta liberação lenta foi semelhante a observada nos testes de intumescimento e resultou 
em uma liberação controlada do fármaco. Assim, o dextrano 70 kDa é um polímero adequado para o 
desenvolvimento de hidrogéis como veículos para a liberação controlada de fármacos.
Unitermos: Hidrogel/desenvolvimento. Hidrogel/propriedades biofarmacêuticas. Dextrano/
desenvolvimento de hidrogel. Praziquantel/liberação controlada. Hidrogel/teste de intumescimento.
INTRODUCTION
Schistosoma mansoni infection causes intestinal 
schistosomiasis and is one of the most common parasitic 
diseases in the tropics and subtropics (Enk et al., 2008). 
One treatment approach for this disease is chemotherapy 
using praziquantel (PZQ). PZQ is a broad spectrum anti-
helminthic drug effective against all important species of 
adult flatworms and their immature forms. The poor bio-
availability of PZQ can be attributed to its fast metabolism 
and low water solubility (Mourão et al., 2005; USP 31, 
2008). According to González-Esquivel et al. (2005), the 
apparent permeability coefficient of PZQ is 4.4 x 10-5 cm/s. 
For this reason, PZQ has been classified as a Class II drug 
in the Biopharmaceutics Classification System (BCS) 
(Passerini et al., 2006; Breda et al., 2009).
Drugs such as praziquantel, as well as those which 
do not have any biopharmaceutical property impaired by 
a physicochemical property, may benefit from improved 
properties with the use of controlled release systems. Drug 
delivery in conventional dosage forms often suffers from 
the drawbacks of repeated drug administration and large 
fluctuations in blood drug levels. Controlled drug delivery 
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systems are a convenient way of controlling the dosing 
frequency responsible for rapid absorption and distribution 
of drug in conventional dosage forms, and are dependent 
upon two intrinsic properties of the drug, namely, elimina-
tion half-life (t1/2) and therapeutic index (TI). The goal is 
to give a drug at a sufficient rate, frequency and dose so 
that the ratio Cmax/Cmin in plasma at steady state is always 
maintained at effective concentrations during the course 
of therapy, reducing side effects or improving physico-
chemical and biopharmaceutical properties. A number 
of controlled release drug delivery systems such as oral, 
transdermal, injectable and implantable drug delivery 
systems have been investigated (Sood, Panchagnula, 2003; 
Sun et al., 2003).
In the development of controlled drug release 
systems, various strategies have employed polymers to 
modify the characteristics of the substances or particles 
thereby improving targeting action, prolonging release or 
decreasing toxicity. The use of polymers in the design of 
systems for controlled drug release has been intensively 
studied in recent years and some authors foresee major 
developments at the interface between the chemistry of 
polymers and the biomedical sciences (Takakura, Hashida, 
1995; Duncan, 2003; Ettmayer et al., 2004).
The main interest in Polymeric Delivery Systems is 
their programmability. The use of these systems provides 
the potential to control drug delivery both temporally and 
spatially. A very simple example is sustained drug release 
from polymeric matrices that generates a continuous 
plasmatic concentration for a prolonged period within 
their therapeutic window, similar to non-polymeric drug 
delivery systems. Polymeric systems for drug delivery can 
be used for several purposes to improve biopharmaceuti-
cal and pharmacokinetic properties of drugs. One of these 
applications is in the dynamic release of insulin from a 
polymeric matrix that occurs only in response to increased 
glucose concentration among diabetic patients. To extend 
blood circulation time, drugs have been encapsulated in 
polymeric nano- or micro- particles. Polymer-drug conju-
gation can also increase drug circulation time and stability 
in blood. The products obtained from those systems thus 
improve drug performance, provide patient convenience, 
and prolong drug stability. Moreover, development of 
these products can also be less expensive than searching 
for new drugs. In addition, re-formulation is an effective 
means of extending patent protection of an existing drug 
(Leong, Langer, 1987; Pillai, Panchagnula, 2001; Kim et 
al., 2009).
Polysaccharides are the most popular of all polymer 
compounds used for drug release systems, due to a number 
of characteristics that make these materials ideal for phar-
maceutical use. These characteristics include the variety 
of chemical functional groups that can be attached to their 
chains for both chemical and biochemical modifications, 
as well as being highly stable, safe, non-toxic, hydrophilic 
and able to form gels upon hydration. Furthermore, poly-
saccharides are biodegradable and thus attractive for use 
in targeted drug-release systems (Sinha, Kumria, 2001; 
Liu et al., 2008; Kim et al., 2009). Examples of poly-
saccharides used for drug release include poly (alginic 
acid), modified starch, dextran and cellulose derivatives, 
which have all been widely used because they control the 
release of the drug, albeit through different mechanisms 
(Adrianov, Payne, 1998; Lopes et al., 2005). Dextran, a 
polymer produced by microorganisms, is nontoxic, bio-
degradable, biocompatible and highly hydrophilic. It can 
be produced in a wide range of molecular weights, giving 
rise to variable physical and chemical properties, such as 
different solubilities and viscosities. Dextran is degraded 
by dextranases in various organs of the human body, such 
as the liver, spleen, kidney and colon (Ferreira et al., 2004; 
Hiemstra et al., 2006; Barsbay, Güner, 2007). Dextran 
and its derivatives are used as plasma expanders, bone 
regeneration promoters and for skin and subcutaneous 
filling. Thus, dextrans number among the most promising 
candidates for the design of hydrogels capable of control-
ling the release of both small molecule and protein drugs 
(Barsbay, Güner, 2007; Coviello et al., 2007) and have 
gained much attention due to their utility in a variety of 
other applications (Van Thienen et al., 2007). Additionally, 
dextrans have helped achieve optimal release and desir-
able therapeutic characteristics in a wide range of systems. 
Hydrogels prepared from naturally occurring polymers 
can therefore confer highly beneficial properties to a drug 
(Hamidi et al., 2008). The objective of this study was to 
develop a modified release system consisting of a dextran 
hydrogel containing praziquantel.
MATERIAL AND METHODOLOGY
Material
Dextran 70000 (TCI®), absolute ethanol 99.5% 
(Synth®), hydrochloric acid 37% (Chemis®), sodium 
lauryl sulphate (BDH Chemicals Ltda.) and Praziquantel 
(Shangai Pharmaceutical®) were used as received.
Method
Preparation of hydrogels and physical mixtures
PZQ and DEX-70 were combined at a ratio of 1:0.5 
(w/w) PZQ:DEX-70. PZQ was then incorporated into 
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hydrogels by the solvent casting process. Briefly, PZQ was 
dissolved by stirring in a water-ethanol solution. Dextran 
was then added. Subsequently, this mixture was placed in 
a rotary evaporator, and held at 55 oC until all solvent was 
removed. Separately, physical mixtures were prepared by 
weighing PZQ and DEX-70 at the same ratio as above, and 
mixing. After mixing, the samples were sieved and stored.
Solubility assays
The solubility of the incorporated PZQ in water was 
determined by dispersing aliquots of hydrogels contain-
ing 10 mg of PZQ in 10 mL of water, according to the 
approach adapted from work carried out by Nepal et al. 
(2010) and Vippagunta et al. (2002). These samples were 
stirred for 24 h, then centrifuged at 3400 rpm for 10 min 
and the amount of dissolved PZQ determined by UV 
spectrophotometry at 263 nm. The experiments were per-
formed in triplicate and results expressed as mean values.
Sample characterisation
The systems were characterized by infrared absorp-
tion spectroscopy (IR), X-Ray diffraction (XRD) and 
differential scanning calorimetry (DSC).
Infrared Absorption Spectroscopy 
To investigate the existence of physical or chemical 
interactions between drug and polymer, absorption spec-
tra in the infrared region were obtained using a Fourier 
transform infrared spectrophotometer (IRPrestige-21, 
Shimadzu®). Samples of PZQ, physical mixture and hy-
drogels mixed with KBr were analysed. The IR spectra 
were recorded and peaks compared to published data.
X-Ray Diffraction (XRD)
The identification of the crystalline structure and/
or amorphous forms of PZQ, DEX, PZQ/DEX physi-
cal mixture and PZQ /DEX hydrogels was carried out 
in diffraction patterns obtained from X-ray diffraction 
on a Siemens ® model D5000 goniometer at a speed of 
0.05/min under Cu-Kα radiation (λ = 1.5406 Å) and scan-
ning X-ray wide angle 2θ of between 4 and 60.
Differential scanning calorimetry (DSC)
For thermal analysis of PZQ, DEX, PZQ/DEX 
physical mixture and PZQ/DEX hydrogels, a DSC-2910 
differential scanning calorimeter (TA Instruments®), 
capable of operating from room temperature up to 
600 °C, was employed. DSC curves were obtained from 
samples of 1.9 to 2.1 mg in aluminium crucibles heated at 
10 °C/min under a nitrogen atmosphere flowing at 
25 mL/min.
Swelling ratio
The swelling ratio of the samples was recorded over 
2 h in an adapted Enslin device (Cury, 2009). For these 
tests, a 0.05 g aliquot of each sample was used, and the 
volume of water absorbed was assessed at time intervals 
of 1, 5, 10, 15, 20, 30, 40, 60, 90 and 120 min. All assays 
were performed in triplicate and the results expressed 
as a percentage of absorbed water relative to the initial 
sample mass.
In vitro dissolution assays
The rate of dissolution of PZQ was evaluated for 
those hydrogels that showed improvement in the water 
solubility of PZQ. The percentage drug dissolved was 
estimated by the method described in USP 31 for PZQ 
tablets, which was adapted to the conditions required 
to analyse the hydrogel parameters. Samples of free 
PZQ, hydrogels or physical mixture (10 mg) were incu-
bated in 150 mL of a dissolution medium composed of 
2 mg/mL sodium lauryl sulphate in 0.1 N HCl. Aliquots of 
this medium were withdrawn at 5, 10, 15, 20, 30, 45 and 
60 min, filtered and analysed by HPLC. On withdrawal, 
each aliquot was replaced with fresh medium.
For the HPLC analysis, a Varian - ProStar system 
for High Performance Liquid Chromatography was used, 
equipped with two solvent injection pumps (Prostar ® / Dy-
namax ® 210/215), a photodiode assay spectrophotometric 
detector (Prostar ® 330 UV-VIS PDA), Star system data 
integration, an injection system (Rheodyne ® VS 7125) 
with a 100 μL loop and a Varian ® HPLC octadecyl silane 
RP 18 column (250 mm, 5 mm particle size). The mobile 
phases were water (55%) and acetonitrile (45%). Aliquots 
of 150 μL of collected sample were injected, and a flow 
rate of 1 mL/min was used.
RESULTS AND DISCUSSION
Preparation of hydrogels
Hydrogels have been widely studied as potential 
systems for drug delivery and, in particular, as a viable 
means of improving the dissolution rate of poorly water 
soluble drugs. The small intestine is highly permeable to 
PZQ, but due to its poor water solubility it has low drug 
bioavailability. Dextran was chosen as the polymeric car-
rier as it is a natural polymer with low toxicity, high bio-
compatibility and biodegradability, and especially because 
it is hydrophilic. All of these properties are considered 
ideal for hydrogels.
The hydrogels were prepared in hydroalcoholic 
solution by the process of solvent casting. In this process, 
F. S. Campos, D. L. Cassimiro, M. S. Crespi, A. E. Almeida, M. P. D. Gremião78
ethanol facilitates drug dissolution and also the physical 
cross-linking of the polymer through intermolecular inter-
actions, such as hydrogen bonding or weaker interactions.
Water then hydrates the polymer, completing the 
formation of the hydrogel. It is likely that during this for-
mation process, there is competition between ethanol and 
the polymer for water molecules, causing the drug to be 
incorporated into the polymer matrix during this process. 
In the present study, this method proved to be successful 
and efficient, as well as being easy to execute and low cost.
Solubility Assays
Figure 1 shows the results of water solubility of 
PZQ for the different samples. All tests were performed 
in triplicate and the results correspond to the mean of the 
three determinations. The solubility of 0.22 mg/mL for 
free PZQ served as a control to assess the influence of the 
polymer carrier on this drug property. The data in Figure 
1 show that the hydrogel altered the drug’s solubility in 
water. The solubility of PZQ in the samples of the 1:0.5 
PZQ:DEX hydrogel was slightly lower than that of the free 
drug. This solubility behaviour reflects the fact that dextran 
is a hydrophilic polymer and PZQ is very poorly soluble 
in water. Thus, the dissolution of the drug is hindered by 
the dextran binding to most of the water.
Infrared Absorption Spectroscopy
The PZQ absorption spectrum (Figure 2a) shows 
an OH stretching band at 3400 cm-1 which, in this case, is 
attributed to the presence of water molecules. The bands 
at 2929.87 cm-1 and 2852.72 cm-1 are CH vibrations of the 
symmetric and asymmetric CH3 and CH2 axial deforma-
tions, which have previously been observed in PZQ-loaded 
nanoparticles by Mainardes et al. (2006). According to 
these authors, a band at 1630 cm-1 stems from carbonyl 
stretching, and is observed at 1649.14 cm-1 (Figure 2a) in 
this case. Furthermore, several overlapping bands are seen 
between 1350 and 1000 cm-1, indicating CN axial defor-
mation (Mainardes et al., 2006). As noted by Stenekes 
et al. (2001) and Pitarresi et al. (2007), in the absorption 
spectrum of dextran (Figure 2b) there is a broad band at 
3448 cm-1, resulting from OH stretching in the polymer 
chain. Stenekes et al. (2001) also reported the presence of 
a band at 2900 cm-1 related to CH/CH2 vibrations, which 
can be observed at 2922 cm-1 and 2924 cm-1 in this experi-
ment (Figure 2b). Comparing the IR absorption spectra of 
the physical mixture and the hydrogel (Figure 3), it can be 
observed that the characteristic functional groups of drug 
and polymer are maintained, confirming the integrity of 
the components in each case.
X-Ray Diffraction
Figure 4 show X-Ray patterns of PZQ, DEX, physi-
cal mixtures and hydrogel. The X-Ray pattern of free PZQ 
shows crystalline structure of drug, as demonstrated by 
sharp and intense diffraction peaks close to 6o, 7.5o and a 
range of peaks between 10o and 30o, similar to those ob-
served by Passerini et al. (2006) and Cheng et al. (2010). 
FIGURE 1 - Solubility of PZQ incorporated into hydrogels 
(Pzq:Dex-70 1:0.5 HG) and physical mixture (Pzq:Dex-70 1:0.5 
MF) in water.
FIGURE 2 - Infrared Spectrum of praziquantel (A) and dextran 
70 kDa (B).
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FIGURE 3 - Infrared Spectrum of Physical Mixture PZQ:DEX-70 
(A) and Hydrogel PZQ:DEX-70 (B).
Dextran presents a broad peak centered at 2θ of 18o, sug-
gesting some level of crystallinity, as noted also by Yuan 
et al. (2009). It is also evident in the physical mixture 
that PZQ maintained peaks close to 6o and 7.5o, although 
the intensity was reduced slightly, whereas the series of 
peaks between 10o and 30o were unchanged. In hydrogel, 
the x-ray pattern showed some changes, such as the peak 
around 6o which did not appear in the pattern and the peak 
at 7.5o that was significantly reduced in intensity. Both X-
Ray patterns failed to show evidence of an X-Ray pattern 
of DEX, probably owing to the concentration of polymer 
in the formulation. In addition, these results showed that 
DEX and PZQ did not interfere with each other in the 
formulation.
Differential Scanning Calorimetry (DSC)
Figure 5 show DSC curves of PZQ, DEX, physical 
mixture and hydrogel. In Figure 5a, the DSC curve for 
praziquantel has a sharp endothermic peak at 137.7 °C. 
This peak corresponds to the melting point of the 
drug and indicates that it is crystalline in nature (Hus-
sein, Abdullah, 1998; Mainardes, Gremião, Evangelista, 
FIGURE 4 - XRD patterns of praziquantel, dextran 70 kDa, 
physical mixture and hydrogel.
2006). As observed by Zhang and Chu (2002), the glass 
transition of dextran can be seen near 220 oC. This glass 
transition temperature indicates that there is no crystal-
line dextran and thus confirms the amorphous structure 
of the polymer. A possible cause of such a high glass 
transition temperature could be the existence of strong 
hydrogen bonds between the macromolecules of dextran 
(Zhang, Chu, 2002). The PZQ:DEX physical mixture 
shows an endothermic peak at 139.4 oC (Figure 5c), in-
dicating that the drug-polymer mixture does not generate 
changes in the thermal behaviour of PZQ. However, the 
PZQ-DEX hydrogel exhibited an endothermic peak at 
138.7 °C, showing a higher energy input than that ob-
served for the equivalent physical mixture. Furthermore, 
both of these energy inputs are lower than that required 
by PZQ (Table I). The amount of energy needed to melt 
the free PZQ is higher in its pure crystals because the 
intermolecular interactions are much stronger in PZQ 
than those between PZQ molecules incorporated into the 
hydrogel or those in the physical mixture. It should also 
be noted that there are interactions between the molecules 
of PZQ and dextran, but these are extremely weak. The 
same interactions occur in the hydrogels, but because 
the drug molecules are further apart within the polymer 
network formed by dextran macromolecules these occur 
in a milder form and consequently the amount of energy 
needed to generate the fusion of PZQ is further reduced.
A summary of data obtained by DSC can be seen in 
Table I. Based on this data, it can be concluded that there 
is a weak solid-solid interaction between the polymer 
and drug, although this did not interfere with the physi-
cochemical properties of the drug, polymer or delivery 
system to a significant extent.
F. S. Campos, D. L. Cassimiro, M. S. Crespi, A. E. Almeida, M. P. D. Gremião80
FIGURE 5 - DSC curves of praziquantel (a), dextran 70 kDa (b), the physical mixture PZQ:DEX-70 (c) and the hydrogel 
PZQ:DEX-70 (d).
TABLE I - DSC data
Sample (mg) Tonset (oC) Tpeak (oC) ΔH (J/g)
PZQ 137.7 141.2 89.87
DEX70 - - -
PZQ:DEX70(1:0.5) 138.7 142.3 74.86
MF-PZQ:DEX70(1:0.5) 139.4 143.2 64.63
Swelling ratio
Figure 6 shows the swelling profile of the samples 
over time. The swelling ratio of samples containing the 
drug was higher than that of the polymer alone. Initially, 
the dextran did not show any swelling, but after 40 min-
utes of contact with the moistened surface of the sintered 
plate, the polymers began to swell until finally, after 120 
minutes, a swelling ratio of 384% was observed. However, 
the hydrogels showed a quite different swelling behaviour 
from that of the free polymer. The dextran hydrogel had a 
swelling ratio of 58% at 10 min, gradually rising to 358% 
in relation to its original weight at 40 min. It then remained 
constant until 90 min, after which time it began to increase, 
continuing to do so until 120 min, at which time it had 
increased by 536%.
An explanation for this swelling pattern is that dex-
FIGURE 6 - Swelling profile of dextrans 70kDa (Dex-70), and 
hydrogel containing praziquantel (PZQ:DEX-70 (1:0.5)).
tran is a linear polymer, by more than 50% of consecutive 
α-(1 → 6) linkage in its main chains, and having side 
chains starting from branched linkages of α-(1 → 2), α-(1 
→ 3) and α-(1 → 4) (Coviello, 2007). These side chains 
are more than likely responsible for the physical interac-
tion between the polymer chains and, consequently the 
formation of the hydrogel networks. The polymer also 
has a large number of hydroxyl groups, responsible for 
the polymer’s hydrophilicity and probably also for the 
formation of hydrogen bonds between polymer chains.
Thus, it is plausible that the chains of dextran are 
bound close together by hydrogen bonds, causing the 
distance between the hydroxyl groups in the chain to be 
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much smaller than the distance between many of the other 
hydroxyl groups in the same molecule. This tight binding 
would hinder the entry of water into the polymer network. 
The presence of the drug may cause a rearrangement of 
the OH groups, increasing the distance between various 
chains of dextran and reducing the amount of free hydroxyl 
groups able to form hydrogen bonds. This rearrangement, 
in turn, would make these groups more available for con-
tact with water and thus accelerate hydrogel formation.
In vitro dissolution assays
Figure 7 shows the results of PZQ release. Accord-
ing to the analysis, the 1:0.5 PZQ:DEX hydrogel sample 
reached the maximal amount of drug released in 60 min. 
The maximal amount of drug released was 10.2%, a value 
much smaller than the 27.6% from the free drug and the 
29.7% from the physical mixture.
From the profile for the 1:0.5 PZQ:DEX hydrogel, a 
continuous release of the drug was observed, proving that 
this dextran hydrogel acted as a controlled drug release 
system. The swelling ratio of hydrogels determines the 
drug release profile. Therefore, it is possible to show a 
relationship between the swelling profiles of the dextran 
hydrogels, noted earlier, and their drug release profiles.
A likely explanation for the observed release profile 
would be that the hydrogel swelling capacity was affected 
by a very strong molecular interaction between the poly-
mer chains, despite the likely rearrangement of the OH 
groups. These types of interactions have also been reported 
in DSC analyses. The existing hydrogen bonds likely par-
FIGURE 7 - Release Profile of hydrogel PZQ: DEX-70 (1:0.5), 
their physical mixture and free drug.
tially hinder the separation of polymer chains, allowing 
for the entry of water, as seen in the swelling tests, but also 
obstruct the outflow of the drug, leading to prolonged drug 
release. This mechanism may afford an improvement in 
various properties of the drug, such as its bioavailability 
and half-life, while also reducing its adverse effects.
CONCLUSIONS
The use of hydrogels as delivery systems for drugs 
has shown interesting results. In the in vitro release assays, 
the profile of PZQ release was prolonged by incorporation 
into dextran molecules, effectively trapping PZQ in the 
matrix and releasing it gradually. 
Swelling analysis proved to be crucial in the char-
acterisation of the hydrogels. While the physical charac-
teristics of a polymer result from its structural properties, 
alterations in swelling rate can change the release profile. 
DSC analysis and IR absorption spectroscopy verified 
the absence of any strong interaction between drug and 
polymer. 
Finally, in addition to the continuous release of PZQ, 
the incorporation of the drug into the polymer matrix could 
give rise to significant changes in several pharmaceutical 
properties of praziquantel, such as its solubility and dis-
solution rate.
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